203 related articles for article (PubMed ID: 22571369)
1. Blocking interleukin-1 as a novel therapeutic strategy for secondary prevention of cardiovascular events.
Abbate A; Van Tassell BW; Biondi-Zoccai GG
BioDrugs; 2012 Aug; 26(4):217-33. PubMed ID: 22571369
[TBL] [Abstract][Full Text] [Related]
2. Interleukin-1 blockade in cardiovascular diseases: a clinical update.
Buckley LF; Abbate A
Eur Heart J; 2018 Jun; 39(22):2063-2069. PubMed ID: 29584915
[TBL] [Abstract][Full Text] [Related]
3. Use of Interleukin-1 Blockers in Pericardial and Cardiovascular Diseases.
Emmi G; Urban ML; Imazio M; Gattorno M; Maestroni S; Lopalco G; Cantarini L; Prisco D; Brucato A
Curr Cardiol Rep; 2018 Jun; 20(8):61. PubMed ID: 29904899
[TBL] [Abstract][Full Text] [Related]
4. Atherothrombosis Prevention and Treatment with Anti-interleukin-1 Agents.
Biondi-Zoccai G; Garmendia CM; Abbate A; Giordano A; Frati G; Sciarretta S; Antonazzo B; Versaci F
Curr Atheroscler Rep; 2020 Jan; 22(1):4. PubMed ID: 31932973
[TBL] [Abstract][Full Text] [Related]
5. Interleukin-1 blockade treatment decreasing cardiovascular risk.
Zheng ZH; Zeng X; Nie XY; Cheng YJ; Liu J; Lin XX; Yao H; Ji CC; Chen XM; Jun F; Wu SH
Clin Cardiol; 2019 Oct; 42(10):942-951. PubMed ID: 31415103
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside.
Buckley LF; Abbate A
BioDrugs; 2018 Apr; 32(2):111-118. PubMed ID: 29549570
[TBL] [Abstract][Full Text] [Related]
7. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases.
Dinarello CA; Simon A; van der Meer JW
Nat Rev Drug Discov; 2012 Aug; 11(8):633-52. PubMed ID: 22850787
[TBL] [Abstract][Full Text] [Related]
8. Interleukin-1β inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS).
Ridker PM; Thuren T; Zalewski A; Libby P
Am Heart J; 2011 Oct; 162(4):597-605. PubMed ID: 21982649
[TBL] [Abstract][Full Text] [Related]
9. Interleukin-1 as a therapeutic target in gout.
Dumusc A; So A
Curr Opin Rheumatol; 2015 Mar; 27(2):156-63. PubMed ID: 25633244
[TBL] [Abstract][Full Text] [Related]
10. Closing the loop on inflammation and atherothrombosis: why perform the CIRT and CANTOS trials?
Ridker PM
Trans Am Clin Climatol Assoc; 2013; 124():174-90. PubMed ID: 23874021
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-1 therapy in the management of gout.
Schlesinger N
Curr Rheumatol Rep; 2014 Feb; 16(2):398. PubMed ID: 24407823
[TBL] [Abstract][Full Text] [Related]
12. [CAPS treatment].
Jiménez Treviño S; Ramos Polo E
Med Clin (Barc); 2011 Jan; 136 Suppl 1():29-33. PubMed ID: 21596184
[TBL] [Abstract][Full Text] [Related]
13. Inflammation and Atherosclerosis: The End of a Controversy.
Hansson GK
Circulation; 2017 Nov; 136(20):1875-1877. PubMed ID: 28916641
[No Abstract] [Full Text] [Related]
14. [Indications and modes of use for interleukin (IL)-1 antagonists in inflammatory dermatosis: a new therapeutic approach to immune-mediated inflammatory diseases].
Lipsker D; Lenormand C
Ann Dermatol Venereol; 2012 Jun; 139(6-7):459-67. PubMed ID: 22721478
[TBL] [Abstract][Full Text] [Related]
15. Use and role of monoclonal antibodies and other biologics in preventive cardiology.
Gencer B; Laaksonen R; Buhayer A; Mach F
Swiss Med Wkly; 2015; 145():w14179. PubMed ID: 26524671
[TBL] [Abstract][Full Text] [Related]
16. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey.
Rossi-Semerano L; Fautrel B; Wendling D; Hachulla E; Galeotti C; Semerano L; Touitou I; Koné-Paut I;
Orphanet J Rare Dis; 2015 Feb; 10():19. PubMed ID: 25758134
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-1 and tumor necrosis factor α blockade treatment of experimental polymyositis in mice.
Sugihara T; Okiyama N; Watanabe N; Miyasaka N; Kohsaka H
Arthritis Rheum; 2012 Aug; 64(8):2655-62. PubMed ID: 22392010
[TBL] [Abstract][Full Text] [Related]
18. Canakinumab for secondary prevention of atherosclerotic disease.
Capodanno D; Angiolillo DJ
Expert Opin Biol Ther; 2018 Feb; 18(2):215-220. PubMed ID: 29265905
[TBL] [Abstract][Full Text] [Related]
19. Interleukin 1β: a proinflammatory target for preventing atherosclerotic heart disease.
McCarty S; Frishman W
Cardiol Rev; 2014; 22(4):176-81. PubMed ID: 24618930
[TBL] [Abstract][Full Text] [Related]
20. Anti-interleukin-1 treatment in 26 patients with refractory familial mediterranean fever.
Kucuksahin O; Yildizgoren MT; Ilgen U; Ates A; Kinikli G; Turgay M; Erten S
Mod Rheumatol; 2017 Mar; 27(2):350-355. PubMed ID: 27328763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
